A Systematic Review of Strategies to Prevent Cisplatin‐Induced Nephrotoxicity

• Published in: The oncologist (Dayton, Ohio) Vol. 22; no. 5; pp. 609 - 619
• Main Authors: Crona, Daniel J., Faso, Aimee, Nishijima, Tomohiro F., McGraw, Kathleen A., Galsky, Matthew D., Milowsky, Matthew I.
• Format: Journal Article
• Language: English
• Published: England AlphaMed Press 01.05.2017
• Subjects: Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Cisplatin; Cisplatin - adverse effects; Cisplatin - therapeutic use; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions - pathology; Evidence-Based Medicine; Female; Humans; Hydration; Kidney - drug effects; Magnesium; Male; Mannitol; Neoplasms - complications; Neoplasms - drug therapy; Neoplasms - pathology; Nephrotoxicity; Symptom Management and Supportive Care; Magnesium; Hydration; Nephrotoxicity; Cisplatin; Mannitol

Introduction Cisplatin, a platinum‐based antineoplastic agent, is the cornerstone for the treatment of many malignancies. Nephrotoxicity is the primary dose‐limiting toxicity, and various hydration regimens and supplementation strategies are used to prevent cisplatin‐induced kidney injury. However,...